EP2658578A1 - Compositions d'hydratation cellulaire contenant des cyclodextrines - Google Patents

Compositions d'hydratation cellulaire contenant des cyclodextrines

Info

Publication number
EP2658578A1
EP2658578A1 EP10821423.0A EP10821423A EP2658578A1 EP 2658578 A1 EP2658578 A1 EP 2658578A1 EP 10821423 A EP10821423 A EP 10821423A EP 2658578 A1 EP2658578 A1 EP 2658578A1
Authority
EP
European Patent Office
Prior art keywords
cyclodextrin
cyclodextrins
water
clathrate
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10821423.0A
Other languages
German (de)
English (en)
Inventor
Lajos Szente
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastpond Laboratories Ltd
Original Assignee
Eastpond Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastpond Laboratories Ltd filed Critical Eastpond Laboratories Ltd
Priority to EP22151736.0A priority Critical patent/EP4043037A1/fr
Publication of EP2658578A1 publication Critical patent/EP2658578A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Abstract

La présente invention concerne une composition qui interagit avec un système cellulaire biologique qui comprend des molécules bioactives avec des surfaces biomoléculaires, des composants cellulaires et des molécules d'eau avec une densité spécifique. La composition comprend un composant biologiquement actif qui est construit pour faire augmenter une activité d'un système cellulaire biologique par augmentation de l'hydratation d'un ou de plusieurs composants de ce système cellulaire. Le composant biologiquement actif peut comprendre un sous-composant clathrate hydrate de carbone primaire qui fait augmenter la structure à liaison H de l'eau, et un sous-composant soluté secondaire. Le composant biologiquement actif peut comprendre un complexe d'inclusion qui est constitué d'un composant clathrate et d'un composé formant un complexe. Le sous-composant clathrate peut comprendre des amyloses ou des cyclodextrines. La présente invention concerne également une boisson et un procédé qui améliorent l'hydratation cellulaire chez un animal, tel qu'un être humain.
EP10821423.0A 2010-12-31 2010-12-31 Compositions d'hydratation cellulaire contenant des cyclodextrines Withdrawn EP2658578A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22151736.0A EP4043037A1 (fr) 2010-12-31 2010-12-31 Compositions d'hydratation cellulaire contenant des cyclodextrines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/003503 WO2012090018A1 (fr) 2010-12-31 2010-12-31 Compositions d'hydratation cellulaire contenant des cyclodextrines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22151736.0A Division EP4043037A1 (fr) 2010-12-31 2010-12-31 Compositions d'hydratation cellulaire contenant des cyclodextrines

Publications (1)

Publication Number Publication Date
EP2658578A1 true EP2658578A1 (fr) 2013-11-06

Family

ID=44146587

Family Applications (2)

Application Number Title Priority Date Filing Date
EP22151736.0A Pending EP4043037A1 (fr) 2010-12-31 2010-12-31 Compositions d'hydratation cellulaire contenant des cyclodextrines
EP10821423.0A Withdrawn EP2658578A1 (fr) 2010-12-31 2010-12-31 Compositions d'hydratation cellulaire contenant des cyclodextrines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP22151736.0A Pending EP4043037A1 (fr) 2010-12-31 2010-12-31 Compositions d'hydratation cellulaire contenant des cyclodextrines

Country Status (8)

Country Link
EP (2) EP4043037A1 (fr)
JP (1) JP2014502612A (fr)
CN (1) CN103491981B (fr)
AU (2) AU2010366535A1 (fr)
BR (1) BR112013016809A2 (fr)
CA (1) CA2822995C (fr)
RU (1) RU2013133723A (fr)
WO (1) WO2012090018A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
WO2014060548A1 (fr) * 2012-10-17 2014-04-24 Sapiotec Gmbh Complexe d'anthocyanidine pour le traitement du myélome multiple
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
EP2931287B1 (fr) 2012-12-11 2017-10-04 Sapiotec GmbH Delphinidin contre les cellules de mélanome
US10117823B2 (en) 2013-03-12 2018-11-06 Primal Therapies, Inc. Dental composition comprising chelator and base
EP2913366A1 (fr) * 2014-02-28 2015-09-02 SapioTec GmbH Complexe à base d'anthocyanidine
JP6075345B2 (ja) * 2014-09-24 2017-02-08 株式会社東洋新薬 コンドロイチン製剤
KR20230169384A (ko) 2019-02-14 2023-12-15 사이클로퓨어, 인코포레이티드 전하 담지 시클로덱스트린 중합체 물질 및 그의 제조 방법 및 사용 방법

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU184066B (en) * 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
JPS6094912A (ja) 1983-10-28 1985-05-28 Masashige Suzuki 体内中性脂肪低減剤
EP0406811A3 (en) * 1989-07-03 1991-08-28 Ajinomoto Co., Inc. Novel clathrate compounds and a drug comprising them
CA2013485C (fr) * 1990-03-06 1997-04-22 John Michael Gardlik Produit solide contenant de petites particules de complexes de cyclodextrine
US5221735A (en) * 1991-02-25 1993-06-22 Hoffmann-La Roche Inc. Cyclodextrin-polyene inclusion complexes
US5681380A (en) * 1995-06-05 1997-10-28 Kimberly-Clark Worldwide, Inc. Ink for ink jet printers
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
WO2000072331A1 (fr) * 1999-05-20 2000-11-30 Bayer Aktiengesellschaft PROCEDE POUR PRODUIRE DES POLYMERES π CONJUGUES
CA2401424C (fr) 2000-03-28 2011-02-08 Farmarc Nederland Bv Complexes d'inclusion d'alprazolame et compositions pharmaceutiques les contenant
JP4675457B2 (ja) * 2000-06-20 2011-04-20 高砂香料工業株式会社 ワニリルアルコール誘導体のサイクロデキストリン包接化合物、及びそれを含有する組成物
US6884885B2 (en) * 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
EP1443969A2 (fr) 2001-10-18 2004-08-11 Decode Genetics EHF Complexes de non-inclusion a base de cyclodextrine
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
EP1499361B1 (fr) 2002-04-19 2012-08-08 Novartis AG Nouvelles biomatieres, leur preparation et leur utilisation
DK1478401T3 (da) 2002-08-19 2010-01-18 Artjen Complexus Inc Sammensætninger omfattende næringsfedt-komplekser og fremgangsmåder til deres avnendelse
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
EP1447013A1 (fr) 2003-02-14 2004-08-18 Wacker-Chemie GmbH Procédé pour réduire l'index glycémique des aliments
US7105195B2 (en) 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
WO2006004574A2 (fr) 2004-02-19 2006-01-12 Abbott Laboratories Methode d'utilisation de gamma cyclodextrine dans la regulation de la glycemie et de la secretion d'insuline
WO2006036159A1 (fr) 2004-09-27 2006-04-06 Cargill, Incorporated Complexes d'inclusion a base de cyclodextrine et leurs procedes de preparation
FR2876914A1 (fr) * 2004-10-21 2006-04-28 Pierre Fabre Medicament Sa Complexe comprenant un antibiotique, une cyclodextrine et un agent d'interaction
US20090214446A1 (en) * 2005-06-13 2009-08-27 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
US8512789B2 (en) 2005-11-23 2013-08-20 The Coca-Cola Company High-potency sweetener composition with dietary fiber and compositions sweetened therewith
JP2009539978A (ja) * 2006-06-13 2009-11-19 カーギル インコーポレイテッド 大粒子シクロデキストリン包接複合体及びその製造方法
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
WO2008148080A2 (fr) * 2007-05-24 2008-12-04 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques de [5(s)-(2'-hydroxyéthoxy)-20(s)-camptothécine]
US20090023682A1 (en) 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
CA2703946A1 (fr) 2007-10-31 2009-05-07 Diffusion Pharmaceuticals Llc Nouvelle classe d'agents therapeutiques qui ameliorent la diffusion des petites molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2012090018A1 *

Also Published As

Publication number Publication date
AU2016201846A1 (en) 2016-04-21
CA2822995A1 (fr) 2012-07-05
RU2013133723A (ru) 2015-02-10
AU2010366535A1 (en) 2013-07-11
JP2014502612A (ja) 2014-02-03
WO2012090018A1 (fr) 2012-07-05
BR112013016809A2 (pt) 2016-09-27
EP4043037A1 (fr) 2022-08-17
CN103491981A (zh) 2014-01-01
CA2822995C (fr) 2021-05-11
CN103491981B (zh) 2017-11-10

Similar Documents

Publication Publication Date Title
CA2822995C (fr) Compositions d'hydratation cellulaire contenant des cyclodextrines
US10610524B2 (en) Cellular hydration compositions
Park et al. Polysaccharides and phytochemicals: a natural reservoir for the green synthesis of gold and silver nanoparticles
JP4479932B2 (ja) 保存安定性に優れたｓ−アデノシル−ｌ−メチオニン含有乾燥酵母の製造方法、その製造物及びその成型された組成物
EP3513660A1 (fr) Compositions fixant la graisse
Pahwa et al. Chitosan-based gastroretentive floating drug delivery technology: an updated review
KR101905937B1 (ko) 안토시아니딘 복합체
Dong et al. Solubilities of quercetin in three β‐cyclodextrin derivative solutions at different temperatures
Fang et al. Enhancing water solubility and stability of natamycin by molecular encapsulation in methyl-β-cyclodextrin and its mechanisms by molecular dynamics simulations
KR20160124134A (ko) 안토시아니딘 복합체
US20220323431A1 (en) Compositions and methods of promoting cellular hydration
US20230020535A1 (en) Compositions and methods of promoting cellular hydration
JP2022167905A (ja) シクロデキストリンを含有する細胞水和組成物
US20220378774A1 (en) Method of promoting cellular hydration by enhancing intracellular permeation
CN105903028B (zh) 含有环糊精的细胞水合组合物
CA3174816A1 (fr) Compositions favorisant l'hydratation cellulaire
JP2017155046A (ja) シクロデキストリンを含有する細胞水和組成物
JP2015044850A (ja) シクロデキストリンを含有する細胞水和組成物
JP2009195198A (ja) クルクミン分散液
Kuranov et al. Complex formation of cyclodextrins with sulfasalazine in buffer solutions
EP2416769B1 (fr) Procede de preparation de complexes moleculaires entre adapalene et des cyclodextrines
Guo et al. Water-Based Environmentally Friendly Pesticide Formulations Based on Cyclodextrin/Pesticide Loading System.
Rajaram et al. Spectral studies on inclusion complexation between 3-hydroxyflavone and 2-Hydroxypropyl-β-cyclodextrin
Kute et al. Preparation & In-Vitro Evaluation Of Inclusion Complexes Of Simvastatin Tablet With Cyclodextrins
Gündoğdu et al. Evaluation of cefpodoxime proxetil complex with hydroxypropyl-β-cyclodextrin in the presence of a water soluble polymer: Characterization and permeability studies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170908

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20220118